Skip to main content

Advertisement

SpringerLink
Log in

CYP2C19*2 polymorphism in Polish peptic ulcer patients

  • Original article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

CYP2C19 isoenzyme of cytochrome P450 in the liver catabolises proton pump inhibitors, one of the therapeutics utilized in Helicobacter pylori eradication therapy, and in this way could influence the eradication effectiveness. The isoensyme contributes also to metabolism of endogenous substances, which derivatives are involved in the pathogenesis of peptic ulceration. CYP2C19*2 polymorphism (rs4244285) changing the CYP2C19 function could be relevant in the predisposition to peptic ulcer disease.

Methods

CYP2C19*2 polymorphism in 197 peptic ulcer patients and 107 healthy subjects of Polish origin by PCR-RFLP method was investigated.

Results

There were no statistically significant differences in genotypes and alleles frequencies for investigated polymorphism between peptic ulcer patients and healthy individuals. No associations between frequencies of particular CYP2C19 genotypes and alleles and the presence of H. pylori infection in peptic ulcer patients were stated. However, significant association between CYP2C19*2 and gender in H. pylori-infected but not -uninfected peptic ulcer individuals was found.

Conclusions

Investigated polymorphism is not a risk factor for peptic ulcer in Polish population. Obtained results could suggested there is some interaction between gender, CYP2C19*2 polymorphism, and pathogenesis of H. pylori infection development. However, this hypothesis should be verified in the further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bartnik W, Celinska-Cedro D, Dzieniszewski J, Łaszewicz W, Mach T, Przytulski K, et al. Guidelines from the Polish Society of Gastroenterology for the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Klin 2014;6(2):41–9.

    Google Scholar 

  2. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646–64.

    Article  CAS  Google Scholar 

  3. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27–36.

    Article  CAS  Google Scholar 

  4. Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003;98:1010–5.

    Article  CAS  Google Scholar 

  5. Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005;61:375–9.

    Article  Google Scholar 

  6. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000;14:1259–66.

    Article  CAS  Google Scholar 

  7. Ishida Y, Goto Y, Kondo T, Kurata M, Nishio K, Kawai S, et al. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. Int J Med Sci 2006;3:135–40.

    Article  CAS  Google Scholar 

  8. Ozdil B, Akkiz H, Bayram S, Bekar A, Akgöllü E, Sandikçi M. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. Turk J Gastroenterol 2010;21:23–8.

    Article  Google Scholar 

  9. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103–13.

    Article  CAS  Google Scholar 

  10. Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006;62:877–80.

    Article  CAS  Google Scholar 

  11. Musumba CO, Jorgensen A, Sutton L, Van Eker D, Zhang E, et al. Pirmohamed M. CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease. Clin Pharmacol Ther 2013;93:195–2030.

    Article  CAS  Google Scholar 

  12. Kaspera R, Totah RA. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol 2009;5:757–71.

    Article  CAS  Google Scholar 

  13. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012;27:9–54.

    Article  CAS  Google Scholar 

  14. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195–200.

    Article  CAS  Google Scholar 

  15. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12.

    Article  CAS  Google Scholar 

  16. Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 2010;66:681–7.

    Article  Google Scholar 

  17. Oh JH, Dong MS, Choi MG, Yoo HW, Lee SB, Park YI, et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol 2009;24:294–8.

    Article  CAS  Google Scholar 

  18. Lee JH, Jung HY, Choi KD, Song HJ, Lee GH, Kim JH. The Influence of CYP2C19Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole. Gut Liver 2010;4:201–6.

    Article  CAS  Google Scholar 

  19. Kobayashi K, Arakawa T. Arachidonic acid cascade and gastric mucosal injury, protection, and healing: topics of this decade. J Clin Gastroenterol 1995;21:S12–7.

    Google Scholar 

  20. Isomura Y, Yamaji Y, Ohta M, Seto M, Asaoka Y, Tanaka Y, et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol 2010;45:1045–52.

    Article  Google Scholar 

  21. Gan CQ, Wang XY, Cao YD, Ye WX, Liu H, Sun YY. Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res 2011;10:3514–9.

    Article  CAS  Google Scholar 

  22. Chau TK, Marakami S, Kawai B, Nasu K, Kubota T, Ohnishi A. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci 2000;67:1719–24.

    Article  CAS  Google Scholar 

  23. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 2004;10:1961–3.

    Article  CAS  Google Scholar 

  24. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, et al. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther 2005;22:1033–40.

    Article  CAS  Google Scholar 

  25. Wu HC, Tuo BG, Wu WM, Gao Y, Xu QQ, Zhao K. Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex, and Helicobacter pylori infection. Dig Dis Sci 2008;53:2650–6.

    Article  Google Scholar 

  26. Schabowski J, Pitera J. Peptic ulcer among rural population in a selected region of south-eastern Poland. Ann Agric Environ Med 2004;11:323–7.

    Google Scholar 

  27. Kekki M, Sipponen P, Siurala M, Laszewicz W. Peptic ulcer and chronic gastritis: their relation to age and sex, and to location of ulcer and gastritis. Gastroenterol Clin Biol 1999;14:217–23.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Łódź, Poland

    Aleksandra Sałagacka-Kubiak, Marta Żebrowska-Nawrocka, Agnieszka Jeleń, Marek Mirowski & Ewa Balcerczak

Authors
  1. Aleksandra Sałagacka-Kubiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marta Żebrowska-Nawrocka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnieszka Jeleń
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marek Mirowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ewa Balcerczak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewa Balcerczak.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sałagacka-Kubiak, A., Żebrowska-Nawrocka, M., Jeleń, A. et al. CYP2C19*2 polymorphism in Polish peptic ulcer patients. Pharmacol. Rep 71, 272–275 (2019). https://doi.org/10.1016/j.pharep.2018.12.011

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2018.12.011

Keywords

Search

Navigation